Eli Lilly (LLY): Future Growth and Stock Potential

This site is a great place for me (@mifsee(2) has been working on company and stock analysis while learning privately.

This is only a record of my personal analysis and the contents may contain errors or information that differs from the actual situation. Please understand in advance when viewing this site.

Introduction.

Eli Lilly (LLY), which has quickly become well known for its obesity treatment drugs, has a wide range of products and is considered a brand with high expectations for future growth potential.
In this section, we will delve deeper into Eli Lilly's business, its unique strengths, and its future prospects.

What is Eli Lilly (LLY)?

• Eli Lilly and Company, headquartered in Indianapolis, Indiana, USAA global research-based pharmaceutical company.
• Founded in 1876 by Colonel Eli Lilly,R&D is the soul of a company" philosophyThe company develops pharmaceutical products under the
• Eli Lilly is,Products in a wide variety of therapeutic areas including diabetes, oncology, autoimmune diseases, neurodegenerative diseases, and painThe company is doing so.
• Eli Lilly employs approximately 42,000 people worldwide and supplies products to more than 110 countries.
• Eli Lilly develops best-in-class medicines in each therapeutic area to improve the health of people around the world.
• R&D expenditures amounted to $9.31 billion per year,The ratio of R&D expenses to net sales is approximately 27.3%.

Typical Products

• Alzheimer's Disease Drugs:There are therapeutic agents such as donnanemab, which are expected to be introduced to the market in the near future.
• Diabetes drugs:Toltz (ixekizumab) and tirzepatide are the focus of attention.
• Anticancer drugs:The company offers a number of anticancer drugs, including Alimta (pemetrexed) and Gemzar (gemcitabine).

Eli Lilly (LLY) company information is below.

• Company Name:Eli Lilly and Company : Eli Lilly and Company
• Date of Establishment: May 10, 1876
• Name of Representative:: David A. Ricks, Ph.
• Official Site: https://www.lilly.com
• Main Businesses: As a global R&D-oriented pharmaceutical company, we are developing therapeutic drugs for diabetes/oncology/autoimmune diseases/neurodegenerative diseases, etc.

What are Eli Lilly's (LLY) main products?

Eli Lilly's main products are as follows

antidiabetic agent

• Trulicity: a GLP-1 receptor agonist, an injectable drug used to manage blood glucose levels; largest revenue generator by 2023 sales.
• Humalog: brand name of insulin lispro, a fast-acting insulin that manages blood glucose levels in diabetic patients.
• JardianceSGLT2 inhibitor with empagliflozin as the active ingredient, used for the treatment of type 2 diabetes mellitus.

oncology drug

• AlimtaPemetrexed is an anticancer drug with pemetrexed as an active ingredient, used for the treatment of non-small cell lung cancer and malignant pleural mesothelioma.
• GemzarGemcitabine is an anticancer drug with gemcitabine as its active ingredient, used in the treatment of pancreatic, lung, and breast cancers.

Drugs for the treatment of autoimmune diseases

• Taltz: The active ingredient is ixekizumab, which is used to treat psoriasis and psoriasis arthropathica.
• Olumiant: A JAK inhibitor whose active ingredient is baricitinib, used for the treatment of rheumatoid arthritis.

Osteoporosis Drugs

• Forteo: A drug with teriparatide as its active ingredient, used to treat osteoporosis patients at high risk of bone fractures.
• Evista: A drug containing raloxifene as an active ingredient, used for the treatment and prevention of osteoporosis in postmenopausal women.

Neurodegenerative Disease Therapeutics

• ProzacSSRI: An SSRI with fluoxetine as the active ingredient, used to treat depression and anxiety disorders.
• StratteraThe active ingredient is atomoxetine, which is used in the treatment of ADHD (Attention Deficit/Hyperactivity Disorder).

These products are part of Eli Lilly's global portfolio of core products that address patient needs in a variety of therapeutic areas.
The company also focuses on research and development of new drugs and continues to provide innovative treatments.

What is Eli Lilly's (LLY) business model?

Eli Lilly develops, manufactures, and markets primarily human and animal health products, and the following are components of its business model

Major Activities

• Research and Development (R&D): Eli Lilly invests heavily in research and development of drugs for diabetes, cancer, and autoimmune diseases, providing innovative treatments for unmet medical needs.
• Manufacturing and Sales: The company manufactures high quality pharmaceutical products and supplies those products to markets around the world. Sales are conducted primarily through the company's internal sales team, which builds direct relationships with healthcare professionals.
• Marketing and Promotion: The company promotes its products by providing information for healthcare professionals and education on the proper use of pharmaceuticals.

customer relations

• Building Relationships with Healthcare Professionals: We build long-term relationships with healthcare professionals by providing them with educational programs and information about our products.
• Patient Support: Provides support programs and educational materials for patients to help them understand and comply with drug treatment. This includes financial assistance programs.

channel

• direct selling: Provide products directly to health care professionals, explaining their use and benefits in detail.
• online platform: Access to a wide range of customers through online information and patient assistance programs.
• Sales through pharmacies and hospitals: Through partnerships with global pharmacy chains and hospitals, the company offers its products widely.

key resource

• Technology and Intellectual Property: Eli Lilly owns a large number of patents, which keeps it competitive in the market.
• Research and Development Facilities: Research facilities around the world are developing new drugs.
• Sales Channels: Through its extensive sales network, the company brings its products to market quickly and efficiently.

Cost Structure

• research and development expenses: Each year, a huge amount of money is invested in research and development to develop innovative drugs.
• Marketing Expenses: To promote its products and expand its market, the company invests a large amount of money in marketing and promotional activities.
• operating expenses: Expenses related to the maintenance of facilities around the world, the manufacture of products, and the payroll of employees.

source of revenue

• Pharmaceutical Sales: The company derives revenues mainly from the sale of drugs for diabetes, oncology, and autoimmune diseases.
• Veterinary Drugs: Through its Elanco division, the company offers pharmaceuticals for livestock and pets.

Eli Lilly's business model is based on innovative research and development and strong customer relationships, which keeps it competitive in the global marketplace.

What's so great about Eli Lilly (LLY)?

Eli Lilly is a world-renowned pharmaceutical company with a wide range of attractions and strengths.

First, Eli Lilly is a well-established pharmaceutical company with a history of more than 140 years, and its long history of consistently delivering innovative drugs is a testament to its reliability and track record.

Eli Lilly's strength lies in its strong research and development capabilities.
The company is annual,Approximately 27% of its sales are invested in R&D, a ratio that is one of the highest in the pharmaceutical industry.
This high investment has resulted in a number of groundbreaking new drugs.
For example, we are developing drugs that are at the forefront of treatment, such as Trulicity, a diabetes treatment, and Alimta, a cancer treatment.

In addition, Eli Lilly specializes in therapies for serious diseases such as diabetes, cancer, and autoimmune diseases, among others,In the treatment of diabetes, we have established ourselves as a pioneer in the field of insulin and are still focusing on the development of new therapies.
This level of expertise is the reason why the company's products are trusted by many medical facilities.

We supply products to more than 110 countries, and our global network allows us to reach a large number of patients and meet the medical needs of different regions.

Eli Lilly contributes to the development of healthcare through five pillars of strength: a long history, strong research and development capabilities, a high level of expertise, global reach, and an extensive support system.

What are Eli Lilly's (LLY) obesity drugs like?

Eli Lilly has developed and offers tirzepatide (tirzepatide) for the treatment of obesity.
The drug is approved by the U.S. Food and Drug Administration (FDA) under the brand name Zepbound.
Chilzepatide is a revolutionary treatment that utilizes the latest research and technology in weight management.

Characteristics of Chilzepatide

Tilzepatide is the first drug to activate two hormone receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1), which suppress appetite, decrease food intake and regulate fat utilization in the body. This mechanism of action promotes weight loss.

Effectiveness and Clinical Trial Results

Clinical trials have shown that tilzepatide is very effective.
For example, in the SURMOUNT-1 study, a mean weight loss of 22.51 TP3T was observed at the highest dose of 15 mg. In the SURMOUNT-2 study, an average weight loss of 15.71 TP3T was reported in obese or overweight adults.

Tilzepatide is a highly effective and innovative treatment for chronic health problems associated with obesity and overweight, and its introduction is expected to help many patients maintain a healthy weight and reduce associated disease risks.

What are Eli Lilly's R&D capabilities and proprietary technologies?

Eli Lilly is known as a leading pharmaceutical company in its research and development (R&D) capabilities and proprietary technologies. Below are its key characteristics.

Research and Development Capability

• High R&D investment Eli Lilly invests approximately 27% of its sales in research and development each year, one of the highest investment ratios in the pharmaceutical industry. This massive investment drives the company's discovery and development of new drugs and innovative treatments for unmet medical needs.
• Extensive global R&D network Eli Lilly has research and development facilities around the world and develops new drugs on a global scale. This enables the company to develop products that meet the medical needs of various regions and provide treatments that comply with the regulations of each country.

proprietary technology

• Developing breakthrough therapies: Eli Lilly and Company has developed a number of breakthrough therapies in the therapeutic areas of diabetes, cancer, autoimmune diseases, and neurodegenerative diseases. Products such as Trulicity, a diabetes treatment, and Alimta, a cancer treatment, have brought significant benefits to many patients.
• Adoption of new modalities: In addition to traditional small molecule drugs, Eli Lilly is employing new modalities such as biotechnology and gene therapy to develop new approaches to refractory diseases and increase therapeutic efficacy.
• Incretin hormone receptor agonist: Tirzepatide (tirzepatide) is a new treatment that activates these receptors and promotes appetite suppression and weight loss, making this technology highly effective in the treatment of obesity and diabetes.
• Global Partnerships: Eli Lilly is actively developing strategic partnerships with other pharmaceutical companies and research institutions to facilitate the sharing of new technologies and collaborative research, and to accelerate the development of innovative therapies. Examples include a joint program with the University of Washington School of Medicine and co-promotion with Boehringer Ingelheim.

Eli Lilly's research and development capabilities and proprietary technologies, supported by innovation and high investment, continue to provide high-quality treatments to patients worldwide.

What is the trading market?

Eli Lilly's stock is traded on the New York Stock Exchange (NYSE). The ticker symbol is "LLY.

Dividends?

Eli Lilly pays a regular dividend, with a dividend yield of approximately 0.61%.

While this dividend yield is relatively low for the pharmaceutical sector, the company's sustained dividend growth emphasizes long-term returns to investors.

What are Eli Lilly's (LLY) sectors, industries, and themes to which it belongs?

sector

Healthcare: Eli Lilly is part of the healthcare sector, providing innovative treatments for serious health problems such as diabetes, cancer, autoimmune diseases, and neurodegenerative disorders. This sector requires advanced technology and research and development to support the health and lives of patients, and Eli Lilly plays an important role in this sector.

type of industry

Pharmaceuticals: Eli Lilly is classified in the pharmaceutical industry. The company's products are essential for the management of complex diseases and are an important means of improving the quality of life of patients.

Themes belonging to

Diabetes Treatment: Eli Lilly has a long history in the treatment of diabetes, developing innovative therapies such as insulin products and GLP-1 receptor agonists. Diabetes treatment is one of the company's primary focuses.

Cancer Treatment: Cancer treatment is another important business area for Eli Lilly. The company offers treatments for several types of cancer, including pemetrexed (Alimta) and gemcitabine (Gemzar). These drugs play a role in improving survival rates and quality of life for many cancer patients.

Autoimmune Disease Treatment: Eli Lilly is developing drugs for autoimmune diseases such as rheumatoid arthritis and psoriasis. Drugs such as Ormiant (baricitinib) and Toltz (ixekizumab) play an important role in the management of these diseases.

What is the size and growth potential of the industry to which Eli Lilly (LLY) belongs?

Industry Size 

Eli Lilly belongs toThe pharmaceutical industry is expected to reach a global market size of approximately $115.5 billion (approximately 13.5 trillion yen) by 2024and, in particular, oncology drugs represent the largest segment of the market, accounting for about 17% of the total by 2022.

growth potential 

The pharmaceutical industry is,Projected to grow at a compound annual growth rate (CAGR) of 6.12% from 2023 to 2030The company has been
This growth is being fueled by an increasing number of chronic diseases, an aging population, and advances in medical technology, which are supporting the market's growing demand for treatments for diabetes, cancer, cardiovascular disease, and other conditions.

Market Trends by Region

The North American market will account for the largest share in 2022, due to its advanced healthcare infrastructure, increasing prevalence of chronic diseases, and the presence of major pharmaceutical companies.Asian and Latin American markets are also expected to grow rapidly in the coming years due to population growth and expanded access to healthcare.

Market Segment

• Product type: Brand-name drugs account for 67.6% of the market, and demand for generic drugs is increasing.
• Molecular type: Small molecule drugs dominate the market, with biopharmaceuticals and biosimilars showing the fastest growth.
• By Disease: Cancer, diabetes, cardiovascular disease, and autoimmune diseases are major market segments.

Like this,The pharmaceutical industry, of which Eli Lilly is a part, is large and growing, and is expected to expand further with the development and widespread use of new treatments.

Who are Eli Lilly's (LLY) competitors?

Eli Lilly's (LLY) main competitors are.

• Pfizer [PFE]:.Pfizer is one of the world's largest pharmaceutical companies, with particular strengths in vaccines and oncology drugs, known for its COVID-19 vaccine Comilnati and many anticancer drugs, and a competitor with global R&D capabilities and manufacturing infrastructure.
• Merck [MRK]:.Merck is a leading pharmaceutical company with strong product lines in oncology, infectious diseases, vaccines, and animal health. In particular, the anticancer drug Keytruda (Keytruda) is widely used worldwide and is one of the key products supporting Merck's growth.
• Johnson & Johnson [JNJ]:.Johnson & Johnson is a multinational company offering a wide variety of pharmaceutical, medical device, and consumer healthcare products. The pharmaceutical division has strengths in anticancer drugs and immunotherapy, and also offers a wide range of products in the medical device field.
• AstraZeneca [AZN]:.AstraZeneca is a pharmaceutical company with a strong pipeline in the areas of oncology, respiratory, cardiovascular, and renal diseases. The company is particularly known for its oncology drugs Tagrisso and Imfinzi.
• Bristol-Myers Squibb [BMY]:. 
• Bristol-Myers Squibb offers innovative products in the areas of immunotherapy, oncology, cardiovascular disease, and immune disorders. The anticancer drugs Opdivo (Opdivo) and Yervoy (Yervoy) are the company's flagship products.
• Abbi [ABBV]:.AbbVie is a biopharmaceutical company focusing on rheumatology and cancer drugs. Representative products include the anti-rheumatic drug Humira, which is widely used worldwide. The cancer drugs Imbruvica and Venclexta are also key products supporting the company's growth.
• Amgen [AMGN]:.Amgen is a global leader in biotechnology, focusing on the development of breakthrough therapies. Representative products include Prolia, a treatment for osteoporosis, Enbrel, a treatment for rheumatoid arthritis, and Kymriah, a treatment for cancer.
• Novo Nordisk [NVO].: Novo Nordisk is a global leader in the field of diabetes and obesity drugs. Representative products include Novolog, an insulin preparation, and Ozempic, a GLP-1 receptor agonist. The company has a long history and extensive experience in the development and manufacture of diabetes medications, providing innovative therapies to patients worldwide.

Eli Lilly, together with these competitors, is contributing to the advancement of the healthcare industry through the research, development, and delivery of innovative medicines worldwide. Each competitor has different strengths and delivers value to patients in a variety of therapeutic areas.

What are Eli Lilly's (LLY) differentiators and advantages over the competition?

Eli Lilly has several key differentiators and advantages over its competitors in the pharmaceutical industry. Below are some of the key points.

differentiator

1. High investment in research and development (R&D): Eli Lilly conducts research and development at a rate of approximately 271 TP3T of sales, well above the industry average, enabling the development of new drugs and the delivery of innovative treatments.
2. Leadership in Diabetes Care: Eli Lilly has a long history and extensive experience in the treatment of diabetes, offering innovative therapies such as insulin preparations and GLP-1 receptor agonists.
3. Unique Product Portfolio: The company has diverse products in a wide range of therapeutic areas, including diabetes, oncology, autoimmune diseases, and neurodegenerative diseases, allowing it to diversify its risk without being dependent on any particular area.
4. Incretin hormone receptor agonist: Tirzepatide (Tirzepatide) is the first drug to simultaneously activate GIP and GLP-1 receptors and is highly effective in the treatment of diabetes and obesity. The introduction of such a new modality contributes to its differentiation from its competitors.

predominance

1. Strong pipeline and new drug development: Eli Lilly has a large number of clinical trials underway, a rich pipeline of new drugs, and future growth potential.
2. Global Market Expansion: The company supplies products to more than 110 countries, and its strength lies in its global reach. The company can respond quickly to the medical needs of each region.
3. Patient Assistance and Education Programs: Eli Lilly's efforts to improve the quality of care through educational programs for healthcare professionals and patients have increased treatment compliance.
4. Sustainable dividend payments: Eli Lilly continues to pay a stable dividend and is focused on returns to investors. It maintains shareholder confidence and enhances its long-term investment attractiveness.

These differentiators and advantages give Eli Lilly a strong competitive edge in the pharmaceutical industry and allow for continued growth and innovation.

What is Eli Lilly's (LLY) growth strategy?

Eli Lilly's growth strategy focuses on combining diverse approaches to achieve sustainable growth and innovation. Below is a description of the company's key growth strategies.

Continued investment in R&D

Eli Lilly's industry-leading, high development investment has fueled the discovery and development of new drugs, particularly innovative therapies to address unmet medical needs. Many clinical trials are underway in the areas of diabetes, oncology, autoimmune diseases, and neuroscience.

Expansion of new drug pipeline

Eli Lilly is,Numerous new drug development projects are underway, with a particular focus on oncology, diabetes, and immunotherapy drugs.This is expected to increase future revenues. For example, the recently approved obesity drug tirzepatide (tirzepatide) offers new value to an existing market.

Strategic Alliances and Acquisitions

Eli Lilly is strengthening strategic alliances with other pharmaceutical companies and research institutions to share technology and knowledge. Also,The company is also actively pursuing acquisitions to expand its important technology and product portfolio,Maintaining competitiveness and developing new market opportunities.

Global Market Expansion

In addition to expanding its market share in existing markets, Eli Lilly is focusing on expanding into emerging markets. In particular, the company is strengthening its presence in growth markets such as Asia and Latin America to bring innovative treatments to patients worldwide.

Use of digital technology and data analysis

The company is using digital technology and data analysis to improve the efficiency and accuracy of its R&D process, which will enable it to increase the success rate of clinical trials and bring new drugs to market faster. The company is also working to realize personalized medicine and precision medicine through the analysis of patient data.

Sustainable business model

Eli Lilly is building a business model that is sustainable from an environmental, social, and governance (ESG) perspective. The company aims to achieve long-term growth while fulfilling its social responsibility as a company through reducing its environmental impact and social contribution activities.

These strategies have enabled Eli Lilly to remain competitive in the pharmaceutical industry and achieve sustained growth.

What is Eli Lilly's (LLY) new drug development pipeline and what is its timeline?

Eli Lilly is,Through a number of ongoing clinical trials and new drug development programs, the company plans to bring a number of innovative treatments to market over the next several years.Below is a schedule of major new drug development after 2024.

Year 2024

• Donanemab:
  • Uses: Treatment of early symptoms of Alzheimer's disease
  • Current Status: FDA approved. Multiple Phase 3 clinical trials are ongoing (TRAILBLAZER-ALZ program).
• Tirzepatide:
  • Uses: Treatment of obesity and obstructive sleep apnea
  • Status: Successful SURMOUNT-OSA trial and FDA approval. It is expected to be launched in the market.
• Mirikizumab:
  • Uses: Treatment of moderate to severe Crohn's disease and ulcerative colitis
  • Status: Applications pending in the U.S. and EU; regulatory decisions expected in 2024.
• Lebrikizumab:
  • Usage: Treatment of moderate to severe atopic dermatitis
  • Current status: a reapplication has been filed and a regulatory decision is expected in late 2024.

After 2025

• Pirtobrutinib (Pirtobrutinib):
  • Application: Treatment of relapsed or refractory mantle cell lymphoma
  • Current status: Approved; further studies are underway for other indications.
• Lepodisiran:
  • Application: Treatment of atherosclerosis
  • Current status: Phase 3 trial is ongoing, with clinical trial results expected by 2025.

These development programs are scheduled to bring new drugs to market as each clinical trial progresses and regulatory approvals are received.

What are Eli Lilly's (LLY) plans for stock splits?

Eli Lilly has not announced plans for a stock split at this time.
However, given the recent surge and growth in the stock price, a stock split could be implemented in the near future. In the past, the company has conducted 2-for-1 stock splits in 1997, 1995, 1989, and 1986.

With the stock price approaching $1,000, the stock split is expected to make it more affordable for investors to purchase. This may promote increased liquidity and more active trading in the stock market.

Eli Lilly (LLY) Financial Results

Eli Lilly's (LLY) financial year ends on December 31.

The schedule for the release of quarterly financial results is as follows.

• First Quarter Results: Around the end of April
• Second Quarter Financial Results: Around the end of July
• Third Quarter Results: Around the end of October
• Fourth Quarter and Full Year Results: Around the end of Jan.

First, we will review the following four indicators to perform a minimum performance analysis of Eli Lilly and Company (LLY).

1. Sales:An indicator of a company's performance and growth.
2. Operating cash flow and operating cash flow margin:An indicator that looks at how much cash a company generates from its services. Margins are considered excellent when they are 15% of that ratio.
3. Operating Income:Profit earned by a company from its core business. An indicator to evaluate a company's performance.
4. EPS:An indicator that looks at a company's earning power "profitability" and "growth potential" in terms of net income per share. The higher the number, the higher the profitability.

Each data is,Investing.com, ,TradingViewSee from

Eli Lilly (LLY) Stock Price

View the current real-time stock price chart (TradingView) for Eli Lilly (LLY).

The chart shows the Relative Strength Index (RSI). Reference as an indicator of market overheating.

*An overbought indicator when the RSI exceeds 70% to 80%, and conversely, an oversold indicator when the RSI falls below 20% to 30%.

Eli Lilly Quarterly: Sales Trends

Quarterly sales forecasts and actual sales and year-on-year changes.

Sales forecasts and actual results are shown in graphs.

Eli Lilly Quarterly: Operating Cash Flow Trends

Quarterly operating cash flow and operating cash flow margin.

Each transition is shown in the graph below.

Eli Lilly Quarterly: Operating Income and Operating Margin Trends

Quarterly operating income and operating margin.

Each transition is shown in the graph below.

Eli Lilly Quarterly: EPS Trends

Quarterly EPS forecast and actual EPS.

Each transition is shown in the graph below.

Eli Lilly Full Year: Sales Trends

This is the sales forecast for the full year and actual sales and year-on-year changes.

Each transition is shown in the graph below.

Eli Lilly Full Year: Operating Cash Flow Trends

Operating cash flow for the full year and operating cash flow margin.

Each transition is shown in the graph below.

Eli Lilly Full Year: Operating Income and Operating Margin Trends

Operating income and operating margin for the full year.

Each transition is shown in the graph below.

Eli Lilly Full Year: EPS Trends

This is the EPS forecast and actual EPS for the full year.

Each transition is shown in the graph below.

What is the future life of Eli Lilly (LLY)?

Eli Lilly's future prospects are considered very bright. That assessment is based on several factors, including

Strong R&D pipeline

Eli Lilly is developing many promising new drugs.Of particular interest are the Alzheimer's disease drug donanemab and the obesity and diabetes drug tirzepatide, which have shown high efficacy in clinical trials and are expected to be brought to market in the next few years.

Market Expansion and Global Development

In addition to expanding its market share in existing markets, Eli Lilly is also aggressively expanding into emerging markets, particularly,The company is strengthening its presence in the Asian and Latin American markets, which is expected to be a driving force for future growth.

Strategic Alliances and Acquisitions

The company is strengthening strategic alliances with other pharmaceutical companies and research institutions to share technology and knowledge.They are also actively making acquisitions and developing new market opportunities.

Use of digital technology and data analysis

Digital technology and data analysis are being used to improve the efficiency and accuracy of the R&D process, enabling a higher success rate in clinical trials and faster time to market for new drugs.

These factors are expected to help Eli Lilly continue its leadership in the pharmaceutical industry and achieve sustained growth.

Eli Lilly (LLY) Q1 FY2024 Financial Summary

• Net sales: $8.768 billion in $, up $26% from $6.960 billion in $ in the same period last year.
• net income:
  • $$2.243 billion on a GAAP basis (+67% y/y).
  • Earnings per share (EPS) was $2.48 (up 66% YoY).
  • Non-GAAP $$ $2.335B (+$60% YoY).
  • Earnings per share (EPS) was $2.58 (up 59% YoY).

Sales of main products

• Mounjaro: Net sales were $1.806 billion, a significant increase from $569 million in the same period last year.
• Trulicity: Net sales were $1.456 billion, down 261 TP3T from the same period last year.
• Verzenio: Net sales were $1.05 billion, up 401 TP3T from the same period last year.
• Jardiance: Net sales were $687 million, up 191 TP3T from the same period last year.
• Taltz: Net sales were $604 million, up 151 TP3T from the same period last year.

Sales by Region

• Sales in the U.S.: $$5.69B, up $28% YoY. The increase was mainly due to higher demand for Mounjaro, Zepbound, and Verzenio.
• Sales outside the U.S.: $3.07 billion in $, up $22% from the same period last year.

R&D and operating expenses

• research and development expenses: $$2.523B, an increase of $27% over the same period last year. This is due to increased expenses for late-stage development assets and additional investment in early-stage research.
• Marketing, sales, and administrative expenses: $1.952B in $, an increase of $12% over the same period last year. This includes increased promotional activities for new products and compensation expenses.

Key Developments and Outlook

• Clinical Trial Results: Phase 3 trial of tirzepatide in the treatment of obstructive sleep apnea has shown positive results.
• Application for Regulation: We have filed mirikizumab for the treatment of Crohn's disease in the US and EU. In addition, lebrikizumab was resubmitted in the U.S. for the treatment of atopic dermatitis.
• Expansion of production capacity: We plan to substantially increase production capacity, especially for incretin-based drugs, to meet the increasing demand.

Future Outlook

• Sales forecast for full year 2024: Revised upward from $$4.24 billion to $$4.36 billion. This is due to the strong performance of Mounjaro and Zepbound and the expansion of their production capacity.
• Earnings Per Share (EPS) Forecast:
  • $13.05 to $13.55 by GAAP standards.
  • $13.50 to $14.00 on a Non-GAAP basis.

Eli Lilly experienced significant growth in the first quarter of 2024, particularly in sales growth of key products. With aggressive investment in R&D and expansion of production capacity, growth is expected to continue in the future.

Eli Lilly (LLY) Q2 FY2024 Financial Summary

• Net sales: $11.3 billion in $, up $36% from $8.3 billion in $ in the same period last year.
• net income:
  • $$2.967B on a GAAP basis, an increase of 68% over the same period last year.
  • Earnings per share (EPS) was $3.28, up 68% YoY.
  • Non-GAAP $$$3.541B, an increase of $86% over the same period last year.
  • Earnings per share (EPS) was $3.92, an increase of 86% over the same period last year.

Sales of main products

• Mounjaro $ $3.091 billion, a significant increase from $ $980 million in the same period last year. The increase in demand within the U.S. is particularly significant.
• Verzenio: $1.332 billion, an increase of 441 TP3T over the same period last year.
• Zepbound: $1.243 billion, new products that were not sold in the same period last year.
• Trulicity: $1.246 billion, down 311 TP3T from the same period last year. Impacted by intensified competition and supply constraints.
• Jardiance: $770M, up $15% y/y.
• Taltz: $825M, up 17% from the same period last year.

Sales by Region

• Sales in the U.S.: $$7.84B, up $42% YoY, driven by sales of Zepbound and Mounjaro.
• Sales outside the U.S.: $3.47B in $, an increase of $25% over the same period last year. Mainly affected by the introduction of Mounjaro KwikPen in various markets.

Costs and Expenses

• research and development expenses: $$2.711B, an increase of $15% over the same period last year. Due to ongoing portfolio investments.
• Marketing and SG&A expenses: $$2.117B, an increase of $10% over the same period last year. New product launches and investment in human resources were the main factors.

Pipeline and Regulatory Developments

• FDA approval of Curamza (Kisunla): Approved for the treatment of Alzheimer's disease.
• Approval of Jaypirca (Jaypirca) in Japan: Approved for the treatment of relapsed or refractory mantle cell lymphoma.
• Application for Tirzepatide (Tirzepatide): Submitted for the treatment of moderate to severe obstructive sleep apnea and obesity in the U.S. and the EU.

Future Outlook

• Full Year Sales Guidance: Revised upward from $4.54 billion to $4.66 billion.
• EPS Forecast:
  • Increased from $15.10 to $15.60 under GAAP standards.
  • Increased to $16.60 from $16.10 on a Non-GAAP basis.

Eli Lilly enjoyed solid growth in the second quarter, with new drugs Manjaro and Zepbound in particular contributing significantly to sales growth. The company also made progress in its pipeline, including FDA approval of Culamza for the treatment of Alzheimer's disease.

Eli Lilly (LLY) Q3 FY2024 Financial Results Summary

Sales and Revenues

• Net sales: Sales for the third quarter were $11,439.1 million, up 20% from the same period last year. Volume growth was primarily driven by new products Mounjaro and Zepbound.
• net income: $970.3 million on a reported basis, with earnings per share (EPS) of $1.07. Non-GAAP EPS was $1.18. In the same period last year, the company reported a loss of $57.4 million.
• gross margin ratio: 81.0%, up from 80.4% in the same period of the previous year.

Increase in orders

• new product: Moonjaro and Zepbound contributed significantly to revenue, driving volume growth. Non-incremental revenues also increased 17% y/y.

Cash Flow

• R&D investment: R&D expenses for the third quarter were $2,734.1 million. Invested especially in advancing clinical trials on tirzepatide (tirzepatide) and amyloid removal.

Performance by Region

• U.S. markets: Sales increased 46% y/y to $7.81 billion. Growth in Moonjaro and Zepbound was the main factor.
• markets outside the U.S.: Revenue decreased 12% y/y to $3.63 billion. Excluding the impact of the sale of the rights to the olanzapine portfolio (Zyprexa), revenue increased 33%.

Future Guidance

• Full year sales forecast for FY2024: Updated from $45.4 billion to $46 billion.
• EPS Guidance: Set at $12.05 to $12.55 on a reported basis and $13.02 to $13.52 on a non-GAAP basis. Continued investment in new product availability and market expansion.

Factors behind the decline in stock prices

• Downward revision of full-year forecast: The company lowered its full-year sales and EPS forecasts, which are now expected to fall short of expectations.
• Impact of the strong dollar: The appreciation of the U.S. dollar had a negative impact on earnings, especially in sales outside the U.S.
• Increase in one-time expenses: Certain one-time costs put pressure on profits and had an impact on financial results.
• Decrease in sales of main products: Sales of Alimta, an anticancer drug, declined 74% YoY, impacted by increased competition.

Eli Lilly continues to see growth and increased impact in the pharmaceutical market with new clinical trial data for diabetes and Alzheimer's disease treatments.

What brokerage firms can I buy shares of Eli Lilly (LLY)?

The following is a list of major brokerages that offer Eli Lilly (LLY) shares. At these brokerages, you can choose to invest as a CFD (Contract for Difference) in addition to direct stock trading as a foreign stock.

I myself mainly use SBI Securities, but some stocks they handle may not be available for purchase. In such cases, I sometimes use CFDs at Saxo Bank Securities or IG Securities.

summary

We have delved into the details of Eli Lilly's (LLY) business, its unique characteristics, competitive advantages, and earnings growth.

Eli Lilly has quickly become well known for its obesity drugs, but its product portfolio is broad and successful with many of its products. The company's development pipeline is also well underway and its future growth potential is seen as very strong.

Very high growth is expected from the sales growth outlook data.

The stock price is relatively high, and the price range is difficult for me personally to invest in, but I would like to gradually hold it for the long term.